0K1R.LViridian Therapeutics, Inc.

À propos

Viridian Therapeutics, Inc. operates as a biotechnology firm dedicated to developing treatments for patients grappling with serious medical conditions. Central to their pipeline are several investigational therapies targeting IGF-1R. This includes VRDN-001, a humanized monoclonal antibody currently advancing through Phase 1/2 clinical trials as a potential therapy for thyroid eye disease (TED). Additionally, VRDN-002, another IGF-1R antibody, is undergoing Phase 1 clinical evaluation. Their portfolio also features VRDN-003, a therapeutic antibody engineered to target IGF-1R, also intended for TED treatment. Known previously as Miragen Therapeutics, Inc., the company officially adopted the name Viridian Therapeutics, Inc. in January 2021. Founded in 2006, Viridian Therapeutics maintains its corporate headquarters in Waltham, Massachusetts.

www.viridiantherapeutics.com

Statistiques clés

Capitalisation

1.70B

BPA

-3.32

Rendement dividende

0.00%

Bêta

0.90

P/B

3.66

ROE

-47.4%

Secteur

Healthcare

Industrie

Biotechnology

PDG

Stephen F. Mahoney

Employés

143

Date IPO

2018-01-29

Pays

US